Advances in biology of multiple myeloma: clinical applications, Blood, vol.104, pp.607-618, 2004. ,
Signalling and survival pathways in multiple myeloma, Eur J Cancer, vol.42, pp.1574-1580, 2006. ,
New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent, Curr Opin Oncol, vol.15, pp.425-430, 2003. ,
-methoxyestradiol overcomes drug resistance in multiple myeloma, Blood, vol.100, issue.2, pp.2187-2194, 2002. ,
Promising preclinical activity of 2-methoxyestradiol in multiple myeloma, Clin Cancer Res, vol.8, pp.3948-3954, 2002. ,
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays, Blood, vol.101, pp.3606-3614, 2003. ,
Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3, J Biol Chem, vol.276, pp.31839-31844, 2001. ,
Nuclear factor-kappa B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis, Blood, vol.103, pp.3175-3184, 2004. ,
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells, Blood, vol.104, pp.3712-3721, 2004. ,
Estrogen receptors in human myeloma cells, Cancer Res, vol.60, pp.1434-1441, 2000. ,
4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27 Kip1 , and modulation of Bcl-2 family members, Clin Cancer Res, vol.11, pp.2345-2354, 2005. ,
Anti-estrogens induce apoptosis of multiple myeloma cells, Blood, vol.92, pp.1749-1757, 1998. ,
SERMs: meeting the promise of multifunctional medicines, J Natl Cancer Inst, vol.99, pp.350-356, 2007. ,
Raloxifeneinduced myeloma cell apoptosis: a study of nuclear factor-?B inhibition and gene expression signature, Mol Pharmacol, vol.69, pp.1615-1623, 2006. ,
Pure oestrogen antagonists for the treatment of advanced breast cancer, Endocr Relat Cancer, vol.13, pp.689-706, 2006. ,
Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma, J Steroid Biochem Mol Biol, vol.100, pp.67-78, 2006. ,
Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems, J Steroid Biochem Mol Biol, vol.102, pp.114-127, 2006. ,
Structure-function relationship of estrogen receptor alpha and beta: impact on human health, Mol Aspects Med, vol.27, pp.299-402, 2006. ,
Integration of the extranuclear and nuclear actions of estrogen, Mol Endocrinol, vol.19, pp.1951-1959, 2005. ,
Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells, Oncogene, vol.20, pp.5420-5430, 2001. ,
Plasma membrane estrogen receptors exists and function as dimers, Mol Endocrinol, vol.18, pp.2854-2865, 2004. ,
Nature of functional estrogen receptors at the plasma membrane, Mol Endocrinol, vol.20, pp.1996-2009, 2006. ,
Lieberherr M: Detection of a raft-located estrogen receptor-like protein distinct from ER alpha, Int J Biochem Cell Biol, vol.38, pp.376-391, 2006. ,
Cancer therapeutics: targeting the dark site of Myc, Eur J Cancer, vol.41, pp.2485-2501, 2005. ,
Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens, Cancer Res, vol.62, pp.3126-3131, 2002. ,
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells, Proc Natl Acad Sci, vol.97, pp.9042-9046, 2000. ,
c-Myc suppresses p21 WAF1/CIP1 expression during estrogen signalling and antiestrogen resistance in human breast cancer cells ,
, J Biol Chem, vol.208, pp.17617-17625, 2005.
Kip1 induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells, Cancer Res, vol.63, pp.4322-4326, 2003. ,
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens, Cancer Res, vol.63, pp.8037-8050, 2003. ,
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis, Clin Cancer Res, vol.9, pp.316-326, 2003. ,
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events, Am J Pathol, vol.162, pp.1449-1461, 2003. ,
Multiple myeloma cell adhesioninduced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B, Blood, vol.87, pp.1104-1112, 1996. ,
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, vol.10, pp.105-115, 1999. ,
Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line, Cancer Res, vol.60, pp.4262-4269, 2000. ,
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu, Blood, vol.101, pp.703-705, 2003. ,
Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation, Leuk Lymphoma, vol.42, pp.1323-1328, 2001. ,
,
, TRAIL/Apo2L ligand selectively induces apoptosis and overcomes resistance in